Skip to main content
. 2021 Jul 21;27(27):4322–4341. doi: 10.3748/wjg.v27.i27.4322

Table 5.

Active pancreas irreversible electroporation clinical trials (source: ClinicalTrials.gov)

Title
Location
Hyperlink
Patients
Estimated completion
An open-label, multicenter, prospective study of IRE (Nano Knife) combined with radiotherapy and chemotherapy in patients with LAPC Shanghai, China https://clinicaltrials.gov/ct2/show/NCT04310553 40 December, 2020
Ablation of unresectable LAPC with IRE system Teaneck, New Jersey, United States https://clinicaltrials.gov/ct2/show/NCT03614910 30 May, 2023
Chemotherapy followed by irreversible electroporation in patients with unresectable LAPC Aalborg, Denmark https://clinicaltrials.gov/ct2/show/NCT04093141 30 May, 2024
Chemotherapy and IRE in the treatment of advanced pancreatic adenocarcinoma Louisville, Kentucky, United States https://clinicaltrials.gov/ct2/show/NCT03484299 20 December, 2023
PANFIRE-3 trial: Assessing safety and efficacy of IRE + Nivolumab + CpG for metastatic pancreatic cancer Amsterdam, North-Holland, Netherlands https://clinicaltrials.gov/ct2/show/NCT04612530 18 October, 2022
Outcomes of ablation of unresectable pancreatic cancer using the nanoknife IRE system Baltimore, Maryland, United States https://clinicaltrials.gov/ct2/show/NCT02041936 12 December, 2021
Immunotherapy and IRE in the treatment of advanced pancreatic adenocarcinoma Louisville, Kentucky, United States https://clinicaltrials.gov/ct2/show/NCT03080974 10 April, 2022
A study of the use of IRE in pancreatic ductal cancer Toronto, Ontario, Canada https://clinicaltrials.gov/ct2/show/NCT03257150 47 September, 2021
Safety and efficacy of IRE for LAPC Seoul, Korea, Republic of https://clinicaltrials.gov/ct2/show/NCT02898649 100 August, 2019
IRE (Nano Knife) for the treatment of pancreatic adenocarcinoma Poitiers, France https://clinicaltrials.gov/ct2/show/NCT03105921 20 June, 2020
IRE for inoperable hepatic and pancreatic malignancy Hong Kong https://clinicaltrials.gov/ct2/show/NCT02822716 35 December, 2021
Phase II/III of randomized controlled clinical research on IRE synchronous chemotherapy for LAPC Guangzhou, Guangdong, China https://clinicaltrials.gov/ct2/show/NCT03673137 120 November, 2021
Anti-tumor immunity induced by IRE of unresectable pancreatic cancer Guangzhou, Guangdong, China https://clinicaltrials.gov/ct2/show/NCT02343835 20 January, 2025
A pivotal study of safety and effectiveness of Nano Knife IRE for stage 3 pancreatic cancer USA, Multicentre https://clinicaltrials.gov/ct2/show/NCT03899636 528 December, 2023
Immunologic signatures following surgery for pancreatic cancer Durham, North Carolina, United States https://clinicaltrials.gov/ct2/show/NCT03001518 30 April, 2027

IRE: Irreversible electroporation; LAPC: Locally advanced pancreatic cancer.